Positions

Overview

  • My research is focused on the use of monoclonal antibodies that bind cancer cell surface receptors for cancer therapy in combination with chemotherapy agents, Wnt inhibitors, or radiation. This research involves investigation of the mechanisms of enhanced cytotoxicity produced by combination treatment. Orthotopic and metastatic breast, ovarian, and pancreatic cancer xenograft models are being used to optimize therapeutic regimens in collaboration with investigators from the Divisions of Gynecologic Oncology and Hematology/Oncology at UAB. We are also investigating the use of small molecule inhibitors of the Wnt pathway produced at Southern Research for cancer therapy and targeting of cancer initiating cells in breast, ovarian, and pancreatic cancer models. Other research involves cancer treatment with alpha-particle emitters conjugated to monoclonal antibodies. In collaboration with investigators at HudsonAlpha Institute for Biotechnology, we are investigating the use of genomics to predict the response of patients with triple-negative breast cancer, ovarian cancer, or pancreatic cancer treated with chemotherapy. Recent efforts involve the use of histone deacetylase inhibitors to upregulate the MHCII pathway and immune response against syngeneic breast and ovarian cancer models, which is being investigated in combination with checkpoint inhibitor therapy.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growthCancer Immunology, Immunotherapy.  68:175-188. 2019
    2018 The antitumor effects of entinostat in ovarian cancer require adaptive immunityCancer.  124:4657-4666. 2018
    2018 Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cellsJournal of Cellular Biochemistry.  119:6216-6230. 2018
    2018 Corrigendum to ‘ 212 Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models’ [Nucl Med Biol 58 (2018) 67–73] (S0969805117303396) (10.1016/j.nucmedbio.2017.12.004))Nuclear Medicine and Biology.  61:71. 2018
    2018 Retraction notice to “SRI36160 is a specific inhibitor of Wnt/<beta>-catenin signaling in human pancreatic and colorectal cancer cells” [Canc. Lett. 389C (2017) 41–48] (S030438351630800X) (10.1016/j.canlet.2016.12.030))Cancer Letters.  422:131. 2018
    2018 Preferential inhibition of Wnt/β-catenin signaling by novel benzimidazole compounds in triple-negative breast cancerInternational Journal of Molecular Sciences.  19. 2018
    2018 Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466Oncotarget.  9:19459-19459. 2018
    2018 212 Pb-labeled antibody 225.28 targeted to chondroitin sulfate proteoglycan 4 for triple-negative breast cancer therapy in mouse modelsInternational Journal of Molecular Sciences.  19. 2018
    2018 212 Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse modelsNuclear Medicine and Biology.  58:67-73. 2018
    2018 CD38 pretargeted RIT of B-cell tumorsBlood.  131:589-590. 2018
    2018 ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damageJournal of Biological Chemistry.  293:984-994. 2018
    2017 Modulation of antitumor immunity with histone deacetylase inhibitorsImmunotherapy.  9:1359-1372. 2017
    2017 Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs.Clinical and Translational Medicine.  6:11. 2017
    2017 Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer CellsJournal of Cellular Biochemistry.  118:2285-2294. 2017
    2017 Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical reviewGynecologic Oncology Reports.  20:81-86. 2017
    2017 B7-H3-targeted 212 Pb radioimmunotherapy of ovarian cancer in preclinical modelsNuclear Medicine and Biology.  47:23-30. 2017
    2017 SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cellsCancer Letters.  389:41-48. 2017
    2017 Retraction of "Design and Synthesis of Novel Cyclic Amine Benzimidazoles for the Treatment of Pancreatic Cancer".Journal of Medicinal Chemistry.  60:7615. 2017
    2017 Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growthOncotarget.  8:44159-44170. 2017
    2017 Genomic regulation of invasion by STAT3 in triple negative breast cancerOncotarget.  8:8226-8238. 2017
    2017 Journey of TRAIL from bench to bedside and its potential role in immuno-oncologyOncology Reviews.  11:26-42. 2017
    2016 RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4Molecular Oncology.  10:1169-1182. 2016
    2016 Ovarian cancer and the immune system — The role of targeted therapiesGynecologic Oncology.  142:349-356. 2016
    2016 Role of nanotechnology and gene delivery systems in TRAIL-based therapiesEcancermedicalscience.  10. 2016
    2016 The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotypeCancer Research.  76:3978-3988. 2016
    2016 Characterization of the interactions between calmodulin and death receptor 5 in triple-negative and estrogen receptor-positive breast cancer cells: An integrated experimental and computational studyJournal of Biological Chemistry.  291:12862-12870. 2016
    2016 A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse ModelsClinical Positron Imaging.  18:325-333. 2016
    2016 Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes.Cancer Immunology Research.  4:390-399. 2016
    2016 SPARC-independent delivery of nab-paclitaxel without depleting tumor stroma in patient-derived pancreatic Cancer xenograftsMolecular Cancer Therapeutics.  15:680-688. 2016
    2016 Surveying the serologic proteome in a tissue-specific kras(G12D) knockin mouse model of pancreatic cancerProteomics.  16:516-531. 2016
    2016 Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974Laboratory Investigation.  96:249-259. 2016
    2016 Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancerOncotarget.  7:17991-18005. 2016
    2016 Niclosamide and its analogs are potent inhibitors of Wnt/ß- catenin, mTOR and STAT3 signaling in ovarian cancerOncotarget.  7:86803-86815. 2016
    2015 Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancerJournal of the Egyptian National Cancer Institute.  27:205-215. 2015
    2015 Dynamic contrast enhanced magnetic resonance imaging of an orthotopic pancreatic cancer mouse modelJournal of Visualized Experiments.  2015. 2015
    2015 S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinaseScientific Reports.  5. 2015
    2015 Dynamic contrast enhanced magnetic resonance imaging of an orthotopic pancreatic cancer mouse modelJournal of Visualized Experiments2015
    2015 Niclosamide analogs for treatment of ovarian cancerInternational Journal of Gynecological Cancer.  25:1377-1385. 2015
    2015 Ovarian and cervical cancer patient derived xenografts: The past, present, and futureGynecologic Oncology.  138:486-491. 2015
    2014 Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?World Journal of Stem Cells.  6:441-447. 2014
    2014 Pazopanib combined with radiation: In vivo model of interactionCancer Biotherapy and Radiopharmaceuticals.  29:247-250. 2014
    2014 Multi-targeted therapy of cancer by niclosamide: A new application for an old drugCancer Letters.  349:8-14. 2014
    2014 Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-β/SMAD signalingOncogene.  33:2620-2628. 2014
    2014 Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancersClinical Positron Imaging.  16:85-94. 2014
    2014 Will detection of microRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer?Journal of the American Medical Association.  311:363-365. 2014
    2014 Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancerCancer Biology and Therapy.  15:1053-1060. 2014
    2014 Effect of niclosamide on basal-like breast cancersMolecular Cancer Therapeutics.  13:800-811. 2014
    2014 Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirusCancer Gene Therapy.  21:264-274. 2014
    2014 Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancerGynecologic Oncology.  134:112-120. 2014
    2014 MicroRNA results may differ with ageOncology Report.  4. 2014
    2014 Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96Gynecologic Oncology.  132:203-210. 2014
    2014 Recurrent read-through fusion transcripts in breast cancerBreast Cancer Research and Treatment.  146:287-297. 2014
    2013 The Wnt/β-catenin pathway in ovarian cancer: A reviewGynecologic Oncology.  131:772-779. 2013
    2013 Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancersMolecular Cancer Therapeutics.  12:2110-2120. 2013
    2013 Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinomaAnnals of Surgical Oncology.  20:3059-3065. 2013
    2013 ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell linesCancer Research.  73:2368-2378. 2013
    2013 The C-Terminal Region Mesd Peptide Mimics Full-Length Mesd and Acts as an Inhibitor of Wnt/β-Catenin Signaling in Cancer CellsPLoS ONE.  8. 2013
    2013 KM method in estimation of Tumor Doubling time in Animal experimentJournal of the American Statistical Association, Section on Nonparametric Statistics.  2013:3611-3615. 2013
    2012 A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancerGynecologic Oncology.  127:420-425. 2012
    2012 Cancer Treatment with Gene Therapy and Radiation TherapyAdvances in Cancer Research.  115:221-263. 2012
    2012 A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic modelPancreas.  41:789-796. 2012
    2012 Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicityBreast Cancer Research and Treatment.  133:437-445. 2012
    2012 Effect of anti-DR5 and chemotherapy on basal-like breast cancerBreast Cancer Research and Treatment.  133:417-426. 2012
    2012 The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cellsGynecologic Oncology.  125:226-230. 2012
    2012 Progress in cancer therapyCancer Biotherapy and Radiopharmaceuticals.  27:1. 2012
    2012 The use of retinoids in ovarian cancer: A review of the literatureInternational Journal of Gynecological Cancer.  22:191-198. 2012
    2011 Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiationRadiotherapy and Oncology.  101:183-189. 2011
    2011 Cellular model of Warburg Effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipinPLoS ONE.  6. 2011
    2011 Relationship between galectin-3 expression and TRAIL sensitivity in breast cancerExpert Review of Anticancer Therapy.  11:1193-1196. 2011
    2011 Molecular targeted approaches for treatment of pancreatic cancerCurrent Pharmaceutical Design.  17:2221-2238. 2011
    2011 Thrombospondin-1 opens the paracellular pathway in pulmonary microvascular endothelia through EGFR/ErbB2 activationAJP - Lung Cellular and Molecular Physiology.  301:79-90. 2011
    2011 Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imagingMolecular Imaging.  10:153-167. 2011
    2011 A phase i study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancerCancer Chemotherapy and Pharmacology.  67:891-897. 2011
    2011 Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer modelGynecologic Oncology.  121:193-199. 2011
    2011 Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cellsCell Growth and Differentiation.  9:403-417. 2011
    2011 Combined modality therapy with TRAIL or agonistic death receptor antibodiesCancer Biology and Therapy.  11:431-449. 2011
    2011 DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 TherapyClinical Positron Imaging.  13:94-103. 2011
    2011 Evaluation of the Effectiveness of Two Drugs Combination Therapy in Vitro Cytotoxicity StudyJournal of the American Statistical Association, Section on Statistical Consulting.  2011:5147-5152. 2011
    2010 KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse modelClinical and Experimental Metastasis.  27:591-600. 2010
    2010 Overcoming TRAIL resistance in ovarian carcinomaGynecologic Oncology.  119:157-163. 2010
    2010 A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancerPancreas.  39:913-922. 2010
    2009 Monoclonal antibodies in the treatment of pancreatic cancerImmunotherapy.  1:223-239. 2009
    2009 Experimental cancer therapy using restoration of NAD+-linked 15-hydroxyprostaglandin dehydrogenase expressionMolecular Cancer Therapeutics.  8:3130-3139. 2009
    2009 CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental gliomaCancer Gene Therapy.  16:794-805. 2009
    2009 Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer modelInternational Journal of Gynecological Cancer.  19:814-819. 2009
    2009 Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1Molecular Pharmacology.  76:81-90. 2009
    2009 Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: A mechanism for immune evasion in cancerJournal of Immunology.  182:7548-7557. 2009
    2009 Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancerClinical Cancer Research.  15:4058-4065. 2009
    2009 Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancerGynecologic Oncology.  113:384-390. 2009
    2009 Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiationCancer Gene Therapy.  16:246-255. 2009
    2008 In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenograftsORL.  71:1-5. 2008
    2008 In Reply to Dr. SpeerInternational Journal of Radiation Oncology - Biology - Physics.  72:1274. 2008
    2008 Immunohistochemistry in the evaluation of neovascularization in tumor xenograftsStain technology.  83:179-189. 2008
    2008 Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase geneMolecular Cancer Therapeutics.  7:2845-2854. 2008
    2008 Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenograftsby diffusion-weighted magnetic resonance imagingCancer Research.  68:8369-8376. 2008
    2008 Molecular targeted therapies for pancreatic cancerAmerican Journal of Surgery.  196:430-441. 2008
    2008 Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effectsVaccine.  26:4314-4319. 2008
    2008 Enhancement of Glioma Radiotherapy and Chemotherapy Response With Targeted Antibody Therapy Against Death Receptor 5International Journal of Radiation Oncology - Biology - Physics.  71:507-516. 2008
    2008 Effect of TRA-8 anti-DR5 monoclonal antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.Journal of Clinical Oncology.  26:14695. 2008
    2008 Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft modelGut.  57:634-641. 2008
    2008 Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11Clinical Cancer Research.  14:2180-2189. 2008
    2008 Erratum: Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma (Gene Therapy (2008) vol. 14 (1111-1119) 10.1038/sj.gt.3302965)Gene Therapy.  15:327. 2008
    2008 Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer modelGynecologic Oncology.  108:591-597. 2008
    2007 TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growthMolecular Cancer Therapeutics.  6:3198-3207. 2007
    2007 EGFR Genomic Gain and Aberrant Pathway Signaling in Pancreatic Cancer PatientsJournal of Surgical Research.  143:20-26. 2007
    2007 Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancerClinical Cancer Research.  13. 2007
    2007 Combination treatment with TRA-8 anti-death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancerClinical Cancer Research.  13. 2007
    2007 Single-photon emission computed tomography imaging with a humanized, apoptosis-inducing antibody targeting human death receptor 5 in pancreas and breast tumor xenograftsCancer Biology and Therapy.  6:1396-1402. 2007
    2007 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancersGynecologic Oncology.  106:614-621. 2007
    2007 TRAIL-receptor antibodies as a potential cancer treatmentFuture Oncology.  3:405-409. 2007
    2007 Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human gliomaGene Therapy.  14:1111-1119. 2007
    2007 Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib responseAnnals of Surgical Oncology.  14:2150-2158. 2007
    2007 Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice modelGynecologic Oncology.  105:291-298. 2007
    2007 Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancerSurgery.  141:464-469. 2007
    2007 High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenograftsMolecular Cancer Therapeutics.  6:866-875. 2007
    2007 ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinibCancer Biology and Therapy.  6:548-554. 2007
    2006 Oncolytic HSV-1 for the treatment of brain tumoursHerpes -Cambridge-.  13:66-71. 2006
    2006 Treatment With Gemcitabine and TRA-8 Anti-Death Receptor-5 mAb Reduces Pancreatic Adenocarcinoma Cell Viability In Vitro and Growth In VivoJournal of Gastrointestinal Surgery.  10:1291-1300. 2006
    2006 Pretargeted radioimmunotherapyInternational Journal of Radiation Oncology - Biology - Physics.  66. 2006
    2006 Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain functionCancer Research.  66:8520-8528. 2006
    2006 TRAIL receptor-targeted therapyFuture Oncology.  2:493-508. 2006
    2006 Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer modelGynecologic Oncology.  101:46-54. 2006
    2006 Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicityCancer Gene Therapy.  13:203-214. 2006
    2006 Gene delivery and gene therapy of prostate cancerExpert Opinion on Drug Delivery.  3:37-51. 2006
    2006 Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array. Application to Hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinomaJournal of Molecular Diagnostics.  8:76-83. 2006
    2005 Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: Clinical implications of abscopal effectsClinical Cancer Research.  11:8773-8781. 2005
    2005 Erratum: Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region (Cancer Biotherapy and Radiopharmaceuticals (2005) 20, 5 (502-513))Cancer Biotherapy and Radiopharmaceuticals.  20:671. 2005
    2005 Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 regionCancer Biotherapy and Radiopharmaceuticals.  20:502-513. 2005
    2005 Intraperitoneal pretarget radioimmunotherapy with CC49 fusion proteinClinical Cancer Research.  11:8180-8185. 2005
    2005 TRAIL death receptor therapy for malignant glioma.Journal of Clinical Oncology.  23:3187. 2005
    2005 TRAIL-mediated induction of apoptosis as a targeted therapy for prostate cancer.Journal of Clinical Oncology.  23:3186. 2005
    2005 The small heat shock protein αB-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3Journal of Biological Chemistry.  280:11059-11066. 2005
    2005 Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomasGene Therapy.  12:407-417. 2005
    2005 Development and analyses of CPT-11 resistant sublines of human colorectal adenocarcinoma cell line, SW-948Proceedings of the American Association of Cancer Research.  46:350-350. 2005
    2005 Radiotargeted gene therapyJournal of Nuclear Medicine.  46. 2005
    2004 Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancerMolecular Therapy.  10:1059-1070. 2004
    2004 Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cellsJournal of Gastrointestinal Surgery.  8:960-970. 2004
    2004 Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structureBioconjugate Chemistry.  15:1264-1274. 2004
    2004 Detection of disseminated breast cancer growth and treatment response using non-invasive bioluminescence imaging.Journal of Clinical Oncology.  22:742. 2004
    2004 Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cellsGene Therapy.  11:658-667. 2004
    2004 Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cellsInternational Journal of Radiation Oncology - Biology - Physics.  58:950-958. 2004
    2004 Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expressionInternational Journal of Radiation Oncology - Biology - Physics.  59:S2-S10. 2004
    2004 Gene expression imaging with radiolabeled peptidesAnnals of Nuclear Medicine.  18:275-283. 2004
    2004 Imaging and Therapy of Tumors Induced to Express Somatostatin Receptor by Gene Transfer Using Radiolabeled Peptides and Single Chain Antibody ConstructsSeminars in Nuclear Medicine.  34:32-46. 2004
    2003 Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer modelClinical Cancer Research.  9:3731-3741. 2003
    2003 Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.Clinical Cancer Research.  9:3731-3741. 2003
    2003 Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibodyJournal of Surgical Research.  111:274-283. 2003
    2003 Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathwayOncogene.  22:2034-2044. 2003
    2003 An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant gliomaInternational Journal of Radiation Oncology - Biology - Physics.  55:1037-1050. 2003
    2003 Invited commentary: targeting of 125I-labeled B lymphocyte stimulator.Journal of Nuclear Medicine.  44:434-436. 2003
    2003 Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug deliveryBioconjugate Chemistry.  14:302-310. 2003
    2003 Targeting of 125I-labeled B lymphocyte stimulatorJournal of Nuclear Medicine.  44:434-436. 2003
    2003 Three-dimensional dose model for the comparison of177Lu-HuCC49ΔCH2 and177Lu-HuCC49 radioimmunotherapy in mice bearing intraperitoneal xenograftsCancer Biotherapy and Radiopharmaceuticals.  18:239-247. 2003
    2002 Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiationInternational Journal of Radiation Oncology - Biology - Physics.  54:1180-1193. 2002
    2002 Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: Implications for a dual modality treatment using capecitabine and irradiationMolecular Cancer Therapeutics.  1:1139-1145. 2002
    2002 Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cellsMolecular Therapy.  6:190-198. 2002
    2002 De novo synthesis of a new diethylenetriaminepentaacetic acid (DTPA) bifunctional chelating agentBioconjugate Chemistry.  13:317-326. 2002
    2002 Synthesis of the first diethylenetriaminepentahydroxamic acid (DTPH) bifunctional chelating agentBioconjugate Chemistry.  13:327-332. 2002
    2002 Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFvGene Therapy.  9:256-262. 2002
    2002 Model prediction of treatment planning for dose-fractionated radioimmunotherapy.Cancer.  94:1264-1269. 2002
    2002 Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: A sensitive method for assessing 5-fluorocytosine toxicity in VitroAnalytical Biochemistry.  301:189-199. 2002
    2002 Rationales, evidence, and design considerations for fractionated radioimmunotherapy.Cancer.  94:1332-1348. 2002
    2002 Targeted radiotherapy with [(90)Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector.Cancer.  94:1298-1305. 2002
    2002 Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomasCancer Research.  62:773-780. 2002
    2002 Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFvGene Therapy.  9:256-262. 2002
    2002 Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in miceRadiology.  223:417-425. 2002
    2001 Gene therapy for the treatment of cancer.Cancer Biotherapy and Radiopharmaceuticals.  16:275-288. 2001
    2001 Detection and measurement of in vitro gene transfer by gamma camera imagingGene Therapy.  8:291-299. 2001
    2001 A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenograftsGynecologic Oncology.  83:432-438. 2001
    2001 An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expressionMolecular Therapy.  4:223-231. 2001
    2001 Simultaneous evaluation of dual gene transfer to adherent cells by gamma-ray imagingNuclear Medicine and Biology.  28:135-144. 2001
    2001 Update: Gene therapy for the treatment of cancerCancer Biotherapy and Radiopharmaceuticals.  16:275-288. 2001
    2000 Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers.Journal of Clinical Oncology.  18:47S-53S. 2000
    2000 A robust summarize-regress procedure for tissue-specific pharmacokineticsJournal of Biopharmaceutical Statistics.  10:251-264. 2000
    2000 Molecular modification of a recombinant anti-CD3ε-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine modelBlood.  96:1157-1165. 2000
    2000 Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with 99mTc or 188ReJournal of Nuclear Medicine.  41:887-895. 2000
    2000 A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivoMolecular Therapy.  2:562-578. 2000
    2000 An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancerMolecular Therapy.  1:545-554. 2000
    2000 Experimental radioimmunotherapySeminars in Radiation Oncology.  10:156-167. 2000
    2000 Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma modelsGene Therapy.  7:1019-1026. 2000
    2000 Gene transfer strategies for improving radiolabeled peptide imaging and therapyQuarterly Journal of Nuclear Medicine.  44:208-223. 2000
    2000 Radiation to control gene expressionGene Therapy.  7:1085-1086. 2000
    2000 Selectivity of tag-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitroClinical Cancer Research.  6:4323-4333. 2000
    1999 Paclitaxel derivatives for targeted therapy of cancer: Toward the development of smart taxanesJournal of Medicinal Chemistry.  42:4919-4924. 1999
    1999 Mouse models for internal radiation dosimetry [4] (multiple letters)Journal of Nuclear Medicine.  40:1969-1970. 1999
    1999 Improved synthesis of the bifunctional chelating agent 1,4,7,10- tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N',N'',N'''-tris(acetic acid)cyclododecane (PA-DOTA)Bioorganic and Medicinal Chemistry.  7:2313-2320. 1999
    1999 Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.Clinical Cancer Research.  5:2994s-3000s. 1999
    1999 Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.Clinical Cancer Research.  5:3153s-3159s. 1999
    1999 Targeting strategies for cancer radiotherapy.Clinical Cancer Research.  5:3048s-3055s. 1999
    1999 Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancerCurrent Opinion in Oncology.  11:187-190. 1999
    1999 In vivo localization of [111In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vectorClinical Cancer Research.  5:383-393. 1999
    1999 Biodistribution Study of 188Re-Labeled Trisuccin-HuCC49 and Trisuccin-HuCC49ΔCH2 Conjugates in Athymic Nude Mice Bearing Intraperitoneal Colon Cancer XenograftsClinical Cancer Research.  5. 1999
    1999 Combined modality therapy of A431 human epidermoid cancer using anti- EGFR antibody C225 and radiationCancer Biotherapy and Radiopharmaceuticals.  14:451-463. 1999
    1999 Cytosine deaminase and herpes simplex virus thymidine kinase gene expression via adenoviral infection of human cholangiocarcinoma cells occurs in the presence of human bileTumor Targeting.  4:29-36. 1999
    1999 Further studies on the protein conjugation of hydroxamic acid bifunctional chelating agents: Group-specific conjugation at two different lociBioconjugate Chemistry.  10:18-23. 1999
    1999 Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectorsCancer Gene Therapy.  6:209-219. 1999
    1998 Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transferCancer Research.  58:5738-5748. 1998
    1998 Comparison of biodistribution of131I CC49 mAb in athymic nude mice bearing LS174T colon cancer xenografts following bolus injection or continuous infusionTumor Targeting.  3:178-190. 1998
    1998 Genetic induction of antigens and receptors as targets for cancer radiotherapyTumor Targeting.  3:122-137. 1998
    1998 Radiosensitization mediated by a transfected anti-ERBB-2 single-chain antibody in vitro and in vivoInternational Journal of Radiation Oncology - Biology - Physics.  42:817-822. 1998
    1998 A mouse bone marrow dosimetry modelJournal of Nuclear Medicine.  39:1243-1247. 1998
    1998 Enhanced in vivo gene delivery to human ovarian cancer xenografts utilizing a tropism-modified adenovirus vectorTumor Targeting.  3:25-31. 1998
    1998 Combined Cytosine Deaminase Expression, 5-Fluorocytosine Exposure, and Radiotherapy Increases Cytotoxicity to Cholangiocarcinoma CellsJournal of Gastrointestinal Surgery.  2:283-291. 1998
    1997 Experimental tumor targeting with radiolabeled ligands.Cancer.  80:2371-2377. 1997
    1997 Synthesis of bombesin analogues for radiolabeling with rhenium-188.Cancer.  80:2354-2359. 1997
    1997 Tumor localization of a radiolabeled bombesin analogue in mice bearing human ovarian tumors induced to express the gastrin-releasing peptide receptor by an adenoviral vector.Cancer.  80:2419-2424. 1997
    1997 Localization of idine-125-mIP-Des-Met14bmbesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transferJournal of Nuclear Medicine.  38:1221-1229. 1997
    1997 Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivoCancer Research.  57:4325-4332. 1997
    1997 Conjugation of unprotected trisuccin, N-[tris[2-[(N-hydroxyamino)carbonyl]ethyl]methyl]succinamic acid, to monoclonal antibody CC49 by an improved active ester protocolBioconjugate Chemistry.  8:766-771. 1997
    1997 Adenoviral-mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivoClinical Cancer Research.  3:1187-1194. 1997
    1997 Synthesis and biodistribution of peptide based 99mTc/186Re- MAGIPG-D612 monoclonal antibody in nude mice bearing colon cancer xenograftsCancer Biotherapy and Radiopharmaceuticals.  12:55-62. 1997
    1997 Synthesis, rhenium-188 labeling and biodistribution studies of a phenolic ester derivative of trisuccinCancer Biotherapy and Radiopharmaceuticals.  12:375-384. 1997
    1997 Use of a novel cross-linking method to modify adenovirus tropismGene Therapy.  4:1387-1392. 1997
    1996 Approaches to enhance cancer radiotherapy employing gene transfer methodsGene Therapy.  3:1042-1068. 1996
    1996 Synthesis of a new class of isothiocyanatopeptide bifunctional chelating agents for coupling to monoclonal antibodiesInternational journal of peptide and protein research.  48:79-86. 1996
    1996 Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen geneGene Therapy.  3:567-580. 1996
    1996 A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiographyInternational Journal of Radiation Oncology - Biology - Physics.  35:165-172. 1996
    1996 Experimental radioimmunotherapy: biological effectiveness and comparison with external beam radiation.Recent Results in Cancer Research ==.  141:9-18. 1996
    1995 Experimental approaches to increase radiolabeled antibody localization in tumorsCancer Research.  55. 1995
    1995 Experimental approaches to increase radiolabeled antibody localization in tumors.Cancer Research.  55:5729s-5732s. 1995
    1995 Fractionated radioimmumotherapy of human colon carcinoma xenografts with131I-labeled monoclonal antibody CC49Cancer Research.  55. 1995
    1995 Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer modelCancer Research.  55. 1995
    1994 A peptide-based bifunctional chelating agent for 99mTc- and 186Re-labeling of monoclonal antibodies.Cancer.  73:769-773. 1994
    1994 Radioiodination of monoclonal antibodies D612 and 17-1A with 3-iodophenylisothiocyanate and their biodistribution in tumor-bearing nude mice.Cancer.  73:808-815. 1994
    1994 Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine.Cancer.  73:999-1005. 1994
    1994 A peptide‐based bifunctional chelating agent for 99mtc‐ and 186re‐labeling of monoclonal antibodiesCancer.  73:769-773. 1994
    1994 Radioiodination of monoclonal antibodies d612 and 17‐1a with 3‐lodophenylisothiocyanate and their biodistribution in tumor‐bearing nude miceCancer.  73:808-815. 1994
    1994 Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridineCancer.  73:999-1005. 1994
    1994 Three‐dimensional reconstruction of monoclonal antibody uptake in tumor and calculation of beta dose‐rate nonuniformityCancer.  73:912-918. 1994
    1993 Synthesis of N-[Tris[2-[[N-(benzyloxy)amino]carbonyl]ethyl]methyl]succinamic Acid, Trisuccin. Hydroxamic Acid Derivatives as a New Class of Bifunctional Chelating AgentsBioconjugate Chemistry.  4:194-198. 1993
    1993 Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenograftsInternational Journal of Radiation Oncology - Biology - Physics.  25:629-638. 1993
    1993 Erratum:'Variations in 3-D dose distributions for 131Indium-labeled monoclonal antibody' (Antibody,Immunoconjugates, and Radiopharmaceuticals,(1992)5(4))Antibody, Immunoconjugates, and Radiopharmaceuticals.  6:96. 1993
    1993 Introduction: Radiolabeled antibody tumor dosimetryMedical Physics.  20:499-501. 1993
    1993 New azomycin acyclonucleoside. Synthesis and biodistribution of radiohalogenated analogues in tumor‐bearing miceJournal of Heterocyclic Chemistry.  30:1351-1355. 1993
    1992 Development of 3-iodophenylisothiocyanate for radioiodination of monoclonal antibodiesInternational journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.  43:1387-1391. 1992
    1992 Improved Delivery of Radiolabeled Anti-Bl Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-Bl Monoclonal AntibodyCancer Research.  52:637-642. 1992
    1992 Therapy with Unlabeled and 131I-labeled Pan-B-Cell Monoclonal Antibodies in Nude Mice Bearing Raji Burkitt's Lymphoma XenograftsCancer Research.  52:6476-6481. 1992
    1992 Three-dimensional tumor dosimetry for radioimmunotherapy using serial autoradiographyInternational Journal of Radiation Oncology - Biology - Physics.  24:329-334. 1992
    1991 [125I]-IPM. Radioimmunoconjugator antibody radiolabeling reagentDrugs of the future.  16:1004-1007. 1991
    1991 Radiotherapy in Mice with Yttrium-90-labeled Anti-Ly1 Monoclonal Antibody: Therapy of Established Graft-versus-Host Disease Induced across the Major Histocompatibility BarrierCancer Research.  51:1891-1897. 1991
    1991 Radiotherapy in Mice with Yttrium-90-labeled Anti-Ly1 Monoclonal Antibody: Therapy of the T Cell Lymphoma EL4Cancer Research.  51:1883-1890. 1991
    1991 18F‐2‐deoxy‐2‐fluoro‐D‐glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron‐emission tomographyCancer.  67:1544-1550. 1991
    1991 A Sensitivity Study of Micro-TLDs for in Vivo Dosimetry of RadioimmunotherapyMedical Physics.  18:1195-1199. 1991
    1991 Effect of backscatter on cell survival for a clinical electron beamRadiotherapy and Oncology.  21:269-272. 1991
    1991 The expression of epidermal growth factor receptor on human bladder cancer: Potential use in radioimmunoscintigraphyJournal of Urology, The.  146:227-231. 1991
    1990 A new conjugating agent for radioiodination of proteins: Low in vivo deiodination of a radiolabeled antibody in a tumor modelBioTechniques.  8:536-545. 1990
    1990 A comparison of 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenograftsInternational Journal of Radiation Oncology - Biology - Physics.  18:1033-1041. 1990
    1990 Comparison of antigen expression on normal urothelial cells in tissue section and tissue cultureJournal of Urology, The.  144:1288-1292. 1990
    1990 New trends in the use of radioimmunoconjugates for the therapy of cancer.Targeted diagnosis and therapy.  3:215-255. 1990
    1989 Radioiodinated iodophenyl maleimide: A potential radioimmunoconjugate with low in vivo deiodinationNUC Compact.  20:145-149. 1989
    1989 The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxinsJournal of Immunology.  142:1755-1766. 1989
    1988 Cytotoxic effects of anti-cd5 radioimmunotoxins on human tumors in vitro and in a nude mouse modelCancer Research.  48:7107-7114. 1988
    1988 Localization and Imaging of Radiolabeled Monoclonal Antibodies Against Colorectal Carcinoma in Tumor-Bearing Nude MiceCancer Research.  48:4256-4260. 1988
    1988 Localization and Imaging with Radioiodine-labeled Monoclonal Antibodies in a Xenogeneic Tumor Model for Human B-Cell LymphomaCancer Research.  48:2475-2482. 1988
    1988 Localization and imaging of radiolabeled monoclonal antibodies against colorectal carcinoma in tumor-bearing nude miceCancer Research.  48:4324-4333. 1988
    1987 Human leukemia cell binding and killing by anti-CD5 radioimmunotoxinsInternational Journal of Radiation Oncology - Biology - Physics.  13:1701-1712. 1987
    1986 Antigenic modulation by anti-CD5 immunotoxinsJournal of Immunology.  136:4721-4728. 1986
    1985 Comparison of the distribution and binding of monoclonal antibodies labeled with 131-iodine or 111-indiumEuropean Journal of Nuclear Medicine.  10:398-402. 1985
    1985 Radiolabeling of monoclonal antibody against carcinoembryonic antigen with 88 Y and biodistribution studiesInternational journal of nuclear medicine and biology.  12:79-82. 1985
    1985 Radiolabeling of monoclonal antibody against carcinoembryonic antigen with 88Y and biodistribution studiesInternational journal of nuclear medicine and biology.  12:79-82. 1985
    1982 Localization of Radiolabeled Antibody in SVT2 Tumor Increases with Immunosuppression of the HostProceedings of the Society for Experimental Biology and Medicine.  171:56-64. 1982
    1980 Localization of radiolabeled mouse alloantibody in a sarcoma induced by 3-methylcholanthreneJournal of Nuclear Medicine.  21:77-80. 1980
    1979 Distribution of radiolabled alloantibodies in mice bearing 3-methylcholanthrene-induced sarcomasCancer Research.  39:3363-3368. 1979
    1974 Preferential in vivo localization of 125I-labeled antibody in a carcinogen-induced syngeneic rat tumor.Progress in Experimental Tumor Research.  19:270-283. 1974
    1972 Effect of Rat Tumor Allografts on the Blood Level of Passively Transferred AlloantibodiesProceedings of the Society for Experimental Biology and Medicine.  139:1197-1201. 1972
    1972 Localization of an 125I-Labeled Rat Transplantation Antibody in Tumors Carrying the Corresponding AntigenProceedings of the Society for Experimental Biology and Medicine.  139:1185-1188. 1972

    Chapter

    Year Title Altmetric
    2018 Novel Biomimetic Microphysiological Systems for Tissue Regeneration and Disease Modeling.  87-113. 2018
    2012 Drugs in clinical trials & future directions.  85-95. 2012
    2010 Cytosine Deaminase/5-Fluorocytosine Molecular Cancer Chemotherapy.  219-242. 2010
    2009 Cancer gene therapy.  589-612. 2009
    2000 Radionuclide dosimetry and radioimmunotherapy of cancer.  21-55. 2000

    Research Overview

  • Cancer immunotherapy; Targeting cancer stem cells; Precision oncology
  • Teaching Overview

  • Radiation biology
  • Education And Training

  • Doctor of Philosophy in Radiation Biology / Radiobiology, University of Rochester 1972
  • Master of Life Sciences in Radiation Biology / Radiobiology, University of Rochester 1970
  • Awards And Honors

    Full Name

  • Donald Buchsbaum